Zheyi Hu

Director, Clinical Pharmacology and Pharmacometrics @ Bristol Myers Squibb

About

1. PhD in DMPK with industry experiences in Clinical Pharmacology and Pharmacometrics. 2. Hands on experience in population PK/PD, exposure-response analysis, PBPK modeling; skilled in using R, NONMEM, Simcyp, Phoenix, etc. 3. A total of 19 first or corresponding authored publications in high-quality journals such as Clinical Cancer Research, Clinical Pharmacokinetics, British Journal of Pharmacology, Journal of Chromatography A, Drug Metabolism and Disposition, European Journal of Cancer, Journal of Mass Spectrometry, Analytical and Bioanalytical Chemistry, etc.

Country

United States

City

San Diego

Industry

Pharmaceuticals

Skill

PBPK modeling, Drug-drug interactions, Pharmacokinetics, Pharmacogenomics, Drug metabolites, ADME of herbal medicine, Drug Interactions, Clinical Development, ADME, In Vitro, Pharmacology, Life Sciences, Cell Culture, DMPK, In Vivo

Experience

Director, Clinical Pharmacology and Pharmacometrics

Bristol Myers Squibb

2023-11 - Present · 2 yrs 11 mos

Clinical Pharmacology, Population PK/PD, Exposure-Response analysis, and PBPK modeling

Associate Director, Clinical Pharmacology and Pharmacometrics

Bristol Myers Squibb

2021-10 - 2023-10 · 2 yrs 1 mo

Senior Research Investigator, Clinical Pharmacology and Pharmacometrics

Bristol Myers Squibb

2019-1 - 2021-9 · 2 yrs 9 mos

Scientist II, Pharmacokinetics

IGNYTA, Inc.

2017-8 - 2018-7 · 1 yr

PBPK and PK/PD modeling to support clinical development

Scientist I, Pharmacokinetics

IGNYTA, Inc.

2015-8 - 2017-8 · 2 yrs 1 mo

Postdoctoral Fellow

The University of Tennessee Health Science Center

2011-11 - 2015-8 · 3 yrs 10 mos

1. Physiologically based pharmacokinetic (PBPK) modeling of impaired carboxylesterase-1 activity: effects on oseltamivir disposition. 2. PBPK modelling and in vivo [I]/Ki accurately predict P-gp-mediated drug-drug interactions with dabigatran etexilate. 3. PBPK Modeling of alvespimycin in mice, rats and humans. 4. In vivo information-guided prediction approach for assessing the risks of drug-drug interactions associated with circulating inhibitory metabolites. 5. Disposition pathway-dependent approach for predicting OATP-mediated drug-drug Interactions. 6. Identification of carboxylesterase-dependent metabolism of dabigatran etexilate. 7. The inhibitory effects of alcohol on human carboxylesterase drug metabolism. 8. ...

Associate scientist

HUTCHMED

2006-6 - 2008-8 · 2 yrs 3 mos

Preclinical DMPK studies to support new drug discovery and development.

Education

University of Chinese Academy of Sciences

Drug metabolism and pharmacokinetics

2008 - 2011 · 3 yrs

1. Pharmacokinetics and metabolism of ginsenosides in humans after oral administration of extract of Panax notoginseng roots. 2. Accurate determination of the anticancer prodrug simmitecan and its active metabolite chimmitecan in various plasma samples based on immediate deactivation of blood carboxylesterases. 3. Pharmacokinetic evaluation of the anticancer prodrug simmitecan in different experimental animals. 4. Association between UGT1A1*28 genotype and irinotecan-induced neutropenia and diarrhea. 5. Sex-dependent differences in CYP3A activity as assessed by midazolam disposition in humans.

Central South University

Clinical Pharmacokinetics

2003 - 2006 · 3 yrs

1. Simultaneous determination of 6β-hydroxycortisol and cortisol in human urine and plasma by HPLC-UV for phenotyping the CYP3A Activity. 2. Endogenous cortisol 6β-hydroxylation clearance for CYP3A phenotyping in humans.